| GOSSAMER BIO INC. |
| USA |
| Gesundheit |
| US38341P1021 / A2PCBS |
| 4GB (Frankfurt) / GOSS (NASDAQ) |
| FRA:4GB, ETR:4GB, 4GB:GR, NASDAQ:GOSS |
| - |
| https://www.gossamerbio.c.. |
|
Gossamer Bio Inc. is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing therapeutics in immunology, inflammation, and oncology. It centers its efforts on seralutinib, an investigational inhaled inhibito..
>Volltext.. |
| 68.64 Mio. EUR |
| 125.02 Mio. EUR |
| 41.69 Mio. EUR |
| -139.56 Mio. EUR |
| -146.55 Mio. EUR |
| -0.65 EUR |
| 174.53 Mio. EUR |
| 32.46 Mio. EUR |
| - |
| 2.16 |
| -62.75% |
| -165.65% |
| - |
| - |
| - |
| - |
| GOSSAMER BIO |
| 19.05.26 |
|